Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRENE.L Regulatory News (RENE)

  • There is currently no data for RENE

Director/PDMR Shareholding

8 Aug 2007 16:58

ReNeuron Group plc08 August 2007 NOTIFICATION OF TRANSACTIONS OF DIRECTORS, PERSONS DISCHARGING MANAGERIAL RESPONSIBILITY OR CONNECTED PERSONS This form is intended for use by an issuer to make a RIS notification requiredby DR 3.1.4R(1). (1) An issuer making a notification in respect of a transaction relating to the shares or debentures of the issuer should complete boxes 1 to 16, 23 and 24.(2) An issuer making a notification in respect of a derivative relating to the shares of the issuer should complete boxes 1 to 4, 6, 8, 13, 14, 16, 23 and 24. (3) An issuer making a notification in respect of options granted to a director/person discharging managerial responsibilities should complete boxes 1 to 3 and 17 to 24. (4) An issuer making a notification in respect of a financial instrument relating to the shares of the issuer (other than a debenture) should complete boxes 1 to 4, 6, 8, 9, 11, 13, 14, 16, 23 and 24. Please complete all relevant boxes in block capital letters. 1. Name of the issuer RENEURON GROUP PLC 2. State whether the notification relates to (i) a transaction notified in accordance with DR 3.1.4R(1)(a); or (ii) DR 3.1.4(R)(1)(b) a disclosure made in accordance with section 324 (as extended by section 328) of the Companies Act 1985; or (iii) both (i) and (ii) A TRANSACTION NOTIFIED IN ACCORDANCE WITH DR 3.1.4R(1)(A). 3. Name of person discharging managerial responsibilities/director JOHN SINDEN - DIRECTOR 4. State whether notification relates to a person connected with a person discharging managerial responsibilities/director named in 3 and identify the connected person 5. Indicate whether the notification is in respect of a holding of the person referred to in 3 or 4 above or in respect of a non-beneficial interest(1) 6. Description of shares (including class), debentures or derivatives or financial instruments relating to shares 7. Name of registered shareholders(s) and, if more than one, the number of shares held by each of them 8. State the nature of the transaction 9. Number of shares, debentures or financial instruments relating to shares acquired 10. Percentage of issued class acquired (treasury shares of that class should not be taken into account when calculating percentage) 11. Number of shares, debentures or financial instruments relating to shares disposed 12. Percentage of issued class disposed (treasury shares of that class should not be taken into account when calculating percentage) 13. Price per share or value of transaction 14. Date and place of transaction 15. Total holding following notification and total percentage holding following notification (any treasury shares should not be taken into account when calculating percentage) 16. Date issuer informed of transaction If a person discharging managerial responsibilities has been granted options by the issuer complete the following boxes 17. Date of grant 7 AUGUST 2007 18. Period during which or date on which it can be exercised 10 YEARS FROM THE 7 AUGUST 2007 SUBJECT TO PERFORMANCE CONDITIONS 19. Total amount paid (if any) for grant of the option NIL 20. Description of shares or debentures involved (class and number) 1,000,000 ORDINARY SHARES 21. Exercise price (if fixed at time of grant) or indication that price is to be fixed at the time of exercise 500,000 ORDINARY SHARES AT AN EXERCISE PRICE OF 21 PENCE PER SHARE; AND 500,000 ORDINARY SHARES AT AN EXERCISE PRICE OF 37.5 PENCE PER SHARE. 22. Total number of shares or debentures over which options held following notification 3,396,680 ORDINARY SHARES (INCLUDING ALL PREVIOUS OPTIONS) 23. Any additional information GRANTED UNDER THE RULES OF THE EMPLOYEE SHARE OPTION SCHEME 24. Name of contact and telephone number for queries MICHAEL HUNT CHIEF EXECUTIVE OFFICER PH: +44(0) 1483302560 Name and signature of duly authorised officer of issuer responsible for making notification Date of notification 8/8/07 This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
8th Dec 20227:06 amRNSPositive iPSC data presented at conference
2nd Dec 20224:40 pmRNSSecond Price Monitoring Extn
2nd Dec 20224:35 pmRNSPrice Monitoring Extension
2nd Dec 20222:00 pmRNSPrice Monitoring Extension
2nd Dec 20227:00 amRNSInterim Results
7th Oct 20227:00 amRNSPositive Exosome data presented at US conference
22nd Sep 20227:00 amRNSReNeuron to present new data at Exosome conference
14th Sep 20227:00 amRNSDirectorate and Executive Changes
9th Sep 202210:58 amRNSResult of AGM
2nd Sep 202211:01 amRNSDirector/PDMR Shareholding
1st Sep 20227:00 amRNSBlock Listing Review and Total Voting Rights
15th Aug 20223:25 pmRNSPosting of AR & Accounts & Notice of AGM
1st Aug 20227:00 amRNSDirectorate Change
15th Jul 20227:00 amRNSGrant of Options
14th Jul 20227:00 amRNSShare Purchase by a Director
13th Jul 20227:00 amRNSShare Purchase by a Director
4th Jul 20227:00 amRNSPreliminary Results
1st Jul 20227:00 amRNSFosun Tech Transfer and Supply Agreement update
20th Jun 20227:00 amRNSNotice of Results
3rd May 20227:00 amRNSReNeuron to present at ISCT 2022 in San Francisco
25th Apr 20227:00 amRNSDirector Declaration
23rd Mar 20227:00 amRNSHolding(s) in Company
22nd Mar 20227:01 amRNSDirectorate Changes
22nd Mar 20227:00 amRNSAppointment of Nominated Adviser and Joint Broker
8th Mar 20227:00 amRNSBlock Listing Review and Total Voting Rights
7th Mar 20224:00 pmRNSHolding(s) in Company
2nd Mar 20227:00 amRNSDirector exit arrangements
11th Feb 20224:41 pmRNSSecond Price Monitoring Extn
11th Feb 20224:36 pmRNSPrice Monitoring Extension
11th Feb 20222:38 pmRNSHolding(s) in Company
11th Feb 20227:00 amRNSDirector Change
10th Feb 20229:49 amRNSHolding(s) in Company
9th Feb 202211:59 amRNSHolding(s) in Company
4th Feb 20225:17 pmRNSHolding(s) in Company
28th Jan 20227:00 amRNSInvestor Presentation
26th Jan 20222:06 pmRNSSecond Price Monitoring Extn
26th Jan 20222:01 pmRNSPrice Monitoring Extension
18th Jan 20224:35 pmRNSPrice Monitoring Extension
18th Jan 20222:06 pmRNSSecond Price Monitoring Extn
18th Jan 20222:00 pmRNSPrice Monitoring Extension
18th Jan 202211:05 amRNSSecond Price Monitoring Extn
18th Jan 202211:00 amRNSPrice Monitoring Extension
18th Jan 20229:05 amRNSSecond Price Monitoring Extn
18th Jan 20229:00 amRNSPrice Monitoring Extension
18th Jan 20227:00 amRNSStrategic update
13th Jan 20227:00 amRNSAdditional agreement with Fosun Pharma for CTX
11th Jan 20227:00 amRNSNew Senior Appointment
17th Dec 20212:00 pmRNSDirector Declaration
30th Nov 20217:00 amRNSInterim Results
19th Nov 20217:00 amRNSCTX-iPSC platform data shows commerical potential

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.